ARCHBOW CONSULTING NEWS

Omnicom Health Group Acquires Archbow Consulting

Understanding Pharmaceutical Market Access Differences in the US and Europe

The Smart Way to Approach Pharmaceutical Reimbursement HUB Innovation

How Cell and Gene Therapy Companies Can Adapt in an Evolving Commercial Landscape

2021 Health System Specialty Pharmacy Trend Report

Happy New Year!

How Healthy are Your Pharmaceutical Patient Access Programs?

6 Ways Pharmaceutical Companies Can Adapt to Improve the Chances of Project Success

The Five Data Sets Every Specialty Pharmaceutical Needs Today

How Healthy is Your Pharmaceutical Distribution Network?

Should Health System Specialty Pharmacies (or IDNs) be Included in Market Access Plans?

Leveraging Hospital Market Research to Impact Future Adoption of Cell and Gene Therapies

Which pharmaceutical HUB design is right for you? Insource vs. Outsource vs. Hybrid.

How Pharma & Biotech Manufacturers Can Prepare for COVID-19 HCP Distribution Revenue Cycle Fallout

Track-and-Trace 101

Pharma Reimbursement HUBs: To Audit, or not to Audit?

The 4 Pillars of a Successful Cell and Gene Therapy Launch

Pharmaceutical Distribution Trends to Watch in 2020

5 Essentials for a Successful Advisory Board Meeting

Archbow expands Specialty Distribution expertise with newest team member: Rob Besse

How to Successfully Support Buy-and-Bill Products

5 Considerations for a U.S. Expanded Access Program

The Hottest Topics in Cell and Gene Therapy Today

The Hidden Competitive Advantage: Project Management